Xiaodi Kou

Dr. Xiaodi Kou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AYAihong Yang
Aihong Yang
CLChang Liu
Chang Liu
JWJiarui Wu
Jiarui Wu
XKXiaodi Kou
Xiaodi Kou
RSRui Shen
Rui Shen

23 February 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AYAihong Yang
Aihong Yang
CLChang Liu
Chang Liu
HZHongwei Zhang
Hongwei Zhang
JWJianhua Wu
Jianhua Wu
XKXiaodi Kou
Xiaodi Kou
XKXiaodi Kou
Xiaodi Kou

30 November 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RSRui Shen
Rui Shen
YCYuhong Chen
Yuhong Chen
XLXiangyu Li
Xiangyu Li
XWXi Wang
Xi Wang
AYAihong Yang
Aihong Yang
XKXiaodi Kou
Xiaodi Kou

5 December 2022 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
JWJianhua Wu
Jianhua Wu
CHChengting Hu
Chengting Hu
AYAihong Yang
Aihong Yang
RSRui Shen
Rui Shen
XKXiaodi Kou
Xiaodi Kou


1 February 2023 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
RSRui Shen
Rui Shen
XKXiaodi Kou
Xiaodi Kou
AYAihong Yang
Aihong Yang
JWJianhua Wu
Jianhua Wu
YCYuhong Chen
Yuhong Chen
Alzheimer's disease (AD) has become the fourth leading cause of death in the world. Due to its complex pathogenesis, there is still a lack of effective drug treatments. Studies have found that the metal dyshomeostasis is closely related to other pathogeneses of AD such as oxidative stress, β-amyloid protein deposits, etc. Therefore, it becomes an important target to find the appropriate metal chelating agents to regulate the metal homeostasis. At the same time, because of the complex pathogenesis, single target drugs cannot achieve good effects. Therefore, current studies are mainly focused on exploring multi-target therapy for AD. In this work, the multi-target studies based on metal chelators and other targets with synergistic anti-AD activities were reviewed. The structural characteristics of different chelating agents were summarized and the structure-activity relationship was analyzed, which provided some valuable clues for the subsequent development of anti-AD multi-target drugs based on metal chelating agents.